The White House scrapped plans to hold a Wednesday meeting at a Baltimore-based vaccine plant from Emergent BioSolutions following an exposé from The New York Times.
The Biden administration also announced plans to conduct an audit of the Strategic National Stockpile after the publication of the article, which described how the biopharmaceutical company lobbied the federal government to buy millions of anthrax vaccine doses.
Over the past ten years, the U.S. government has devoted almost half of its stockpile budget to BioSolutions’ anthrax vaccine, leaving a dearth of funding for pandemic response.
Get the full story from our sister site, Pharmaceutical Processing World.